Sutro Biopharma (STRO) Operating Expenses (2017 - 2025)

Sutro Biopharma's Operating Expenses history runs 9 years deep, the most recent figure standing at $49.7 million for Q4 2025.

• In Q4 2025, Operating Expenses fell 37.93% year-over-year to $49.7 million; the TTM figure through Dec 2025 stood at $260.9 million (down 13.19% YoY), while the FY2025 annual figure was $260.9 million, down 13.19% from the prior year.
• Operating Expenses came in at $49.7 million for Q4 2025 at Sutro Biopharma, down from $58.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $85.9 million in Q1 2025 to a low of $33.7 million in Q1 2021.
• A 5-year average of $58.1 million and a median of $57.2 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 51.87% in 2021 and sank 37.93% in 2025, its largest moves.
• Sutro Biopharma's Operating Expenses stood at $45.7 million in 2021, then advanced by 26.62% to $57.9 million in 2022, then gained by 21.98% to $70.6 million in 2023, then rose by 13.46% to $80.1 million in 2024, then slumped by 37.93% to $49.7 million in 2025.
• According to Business Quant data, Operating Expenses over the past three periods registered $49.7 million, $58.2 million, and $67.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison